Colesevelam · PIN 09858334 · 625 mg · tablet
Temporary benefitOntario PIN; no Health Canada record under this code
StatusTemporary benefit
Write on scriptcheck temporary-benefit rules below
Patient paysNot paid by ODB 65 and over; see alternatives
No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Check Health Canada brand searchPrivate plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
No interchangeable product listed in the Ontario extract
Colesevelam · DIN 09858334
Manufacturer: Glenmark Pharmaceuticals Canada Inc.; listing date 2024-04-30
No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN.
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Colesevelam: Formulary list price $0.59 per unit (the source does not state the unit; exact figure $0.5931). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Ontario PIN; see Health Canada brand lookup · Verify on the e-Formulary ↗ (DIN 09858334)
Source record
DIN 09858334: Colesevelam
Raw flags: chronicUseMed=Y, sec3c=Y
Item: 240600077; group id 300; item number 0654; lccId None; manufacturer id GLP
Source form: Tab; strength: 625mg
Recorded listing: Temporary benefit (shortage substitute); chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.5931; ministry $0.5931
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=09858334
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Therapeutic Notes (formulary)
Colesevelam Hydrochloride is indicated for the reduction of cholesterol blood level in patients with hypercholesterolemia (Frederickson Type IIa) as an adjunct to diet and lifestyle changes, when the response to these measures has been inadequate, in patients:
. who are not adequately controlled with an HMG-CoA reductase inhibitor (statin) alone,
or
. who are unable to tolerate a statin.
Shortage status: not checked (no credentials)